Recent events
Recent events tied to this brand in public sources.
Back to profile1 entries
2019
BioVersys receives CARB-X development funding
BioVersys announced US$3.94 million in non-dilutive funding from CARB-X for development of its BV200 anti-virulence program, with the possibility of an additional US$4.98 million if certain project milestones are met.